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Abstract 
 
In non-inferiority trials, the goal is to show how an experimental treatment is statistically 
and clinically not inferior to the active control.  The three-arm clinical trial usually 
recommended for non-inferiority trials by the FDA. The three-arm trial consists of a 
placebo, reference, and an experimental treatment.  The three-arm trial shows the 
superiority of the reference over the placebo and comparison of the reference to an 
experimental treatment.  In this paper, I will assess a non-inferiority trial with Bayesian 
methods.  By employing Bayesian analysis, the parameters are random and assign vague 
prior distributions.  I will compare the models involving different prior distributions to 
assess the best fit model. 
 
Keywords:  Bayesian methods; Gold Standard Design: Markov Chain Monte Carlo; non-
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Introduction 
Non-inferiority trial is a trial with the objective of showing how an experimental 
treatment is statistically and clinically not inferior to the active control (Agostion, 173).  
Clinical trial for establishment of non-inferiority of a test therapy as compared to an 
active control agent has become very popular in drug research and development (Chow, 
2005).  Non-inferiority studies are typically confirmatory trials that employ a randomized 
parallel group design with an active control group.  Some trials also include a placebo 
control group.  The placebo is used to validate the study and to demonstrate superiority of 
the test treatment to the placebo (Garrett, 2003).  Non-inferiority methods are frequently 
used in more serious, acute, and sometimes life-threatening indications such as oncology 
and infectious diseases (Garrett, 2003).   In these cases the primary endpoint is often a 
binary outcome measure and in some cases the trials objective will incorporate a time to 
event evaluation (Garrett, 2003) 
Placebo controlled trials are ideal for evaluating medical treatment efficacy.  These trials 
allow for control of the placebo effect.  Also they require the smallest number of patients 
to detect a treatment effect (D’Agostino 200).  In the absence of effective treatments, 
placebo-controlled Randomized Clinical Trials are uncontroversial.  
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Gold Standard design 
Three-arm trial includes placebo, active control, and the new treatment referred to as gold 
standard design.  Non-inferiority implies that a patient who has previously been treated 
with the reference can be switched to the new experimental treatment without a relevant 
loss in efficacy.  Second, given that the treatment effect of the reference (comparator) is 
of clinical relevance, non-inferiority with an adequately chosen margin results in 
clinically relevant efficacy over placebo.  The three arm trial has the ability to show 
substantial superiority of the comparator over the placebo can be assessed prior to the 
comparison of reference and new experiment treatment (Hauschke and Pigeot, 2005). 
 In dealing with a three arm clinical trail, the investigation on the efficacy of a new 
experimental treatment relative to an active control is the main focus.  For this type of 
trial, there are two clinical settings considered when evaluating relative efficacy.  In the 
first setting, non-inferiority implies that a patient who has previously been treated with 
the reference can be switched to the new experimental treatment without a relevant loss 
in efficacy.  The second setting, given that the treatment effect of the reference is of 
clinical relevance, non-inferiority with an adequately chosen margin results in clinical 
relevant efficacy over the placebo.  In this setting, the three arm trial is recommended 
because of assay sensitivity. Assay sensitivity is the ability of the study to show 
substantial superiority of the reference over the placebo can be assessed prior to the 
comparison of the reference and the new experimental treatment ( Hauschke and Pigeot, 
2005).   
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Margins 
 In a placebo-controlled clinical trial, it is not sufficient to just demonstrate a 
statistically significant treatment difference.  The choice of non-inferiority margin 
requires that in order to demonstrate superiority of a new product over a placebo, not only 
does it has to be statistical significance but also clinical relevance have to be shown.  
 The consideration of the margin  in a non-inferiority test is important.  A different 
choice of non-inferiority margin may affect the method of analyzing clinical data and the 
conclusion  of the clinical study.  The guidelines of the International Conference on 
Harmonization, the determination of non-inferiority margins should be based on both 
statistical reasoning and clinical judgment.  The non-inferiority margin should be chosen 
to satisfy at least the following two criteria (D’Agostion, 2003): 
 
Criterion1: We want the ability to claim that the test therapy is non-inferior to the 
active control agent and is superior to the placebo ( even though the 
placebo is not considered in the active control trial). 
  
Criterion2: The non-inferiority margin should be suitably conservative and variability 
should be taken into account.  
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A fixed margin that does not depend on any parameter is rarely suitable under criterion1.  
Let us define some notation. 
Tθ  unknown test therapy population efficacy  
Aθ  unknown active control agent population efficacy 
pθ  unknown placebo population efficacy 
Δ  ≥  0 a non-inferiority margin 
 
Let 0>δ  be a superiority margin if a placebo-controlled trial is conducted to establish 
the superiority of the test therapy over a placebo control.  Since the active 
control is an established therapy, we may assume that  
 
Aθ  - pθ  >δ  
However, when  
    Tθ  - Aθ  > - Δ   
The test therapy is non-inferior to the active control.  For a fixed  τ  we can not ensure 
that   
    Tθ - pθ >δ  
The test therapy is superior to the placebo unless Δ=0 
Thus, it is reasonable to consider non-inferiority margins depending on unknown 
parameters. 
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 In a fequentist view for non-inferiority trial, it is necessary to pre-specify a fixed 
margin.  This is important because the margin determines the null hypothesis.  For a 
margin to properly represent the maximal acceptable loss in a known beneficial effect, 
the subject assessment must account for the factors other than the effectiveness (Hung 
2005).  Other factors involved such as, benefit versus risk or price to be paid with the 
experimental treatment.  IF there is not a universally accepted metric for the benefit/risk 
assessment, the fixed margin is almost impossible to determine just on assessment (Hung, 
2005). 
 The non-inferiority margin should be selected to provide a sufficient cushion to 
protect the test from possibly being seriously biased. 
The FDA has considered non-inferiority margins dependent upon the highest of 
the two observed response percentage being compared (The FDA is now in the process of 
reviewing this recommendation) The CPMP has fixed the non-inferiority margin at about 
10 per cent.  For many non-serious infections (Garrett , 2003)   
The International Conference on Harmonisation offers 2 guidelines 
 
1. The determination of the margin in non-inferiority trials is based on both 
statistical reasoning and clinical judgment and should reflect uncertainties in the 
evidence on which the choice is based and should be suitably conservative. 
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2. This non-inferiority margin cannot be greater than the smallest effect size that the 
active drug would be reliably expected to have compared with placebo in the 
setting of a placebo controlled trial. 
D’Agostino (2003) states that he has never seen a case where criteria 1 have been 
employed.  Some researchers feel the active control treatment and the new treatment 
should be within some percent of each other.  The ICH feels the control and new 
treatment should be 20 percent while the FDA says 10 percent.    From general 
guidelines, there are only concrete suggestions on the choice of non inferiority margin for 
specific indications (Lange and Freitag, 2005). 
 
Assay Sensitivity 
 Assay sensitivity means the ability within a trial to detect any difference between 
groups.  With respect to clinical trials, detect differences between effective, less effective, 
and ineffective therapies.   
Assay sensitivity is an important issue for non-inferiority trials.  The International 
Conference on Harmonization states that assay sensitivity is inherent in superiority trails.  
This occurs because rejection of the null hypothesis is concluded when there is a 
significant difference in the endpoint for the two arms and the difference validates the 
assay.  In non-inferiority trials, rejection of the null hypothesis is concluded when the 
endpoints for the two arms are close to each other (Aras, 2001).  There is a concern with 
this evaluation.   Both arms may not have performed as intended. In particular, we could 
have proved that a placebo is not inferior to a placebo.    In order not to make this 
mistake, in addition to showing non-inferiority, we must establish the assay sensitivity 
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external to the trials.  We can establish this by including historic evidence or by including 
a small placebo arm in the trial and performing secondary comparisons with respect to it.  
With a small placebo arm, there may not be adequate power to separate treatments from 
the placebo.  However, a trend in the right direction for comparison of treatments with 
the placebo combined with historic data on the control arm my help to argue assay 
sensitivity (Aras 2001). 
 
Placebo-Controlled trials 
An appropriate control group is always essential and when feasible, a placebo control 
is optional.  An active control with the test treatment indicates that the two treatments are 
similar.  Now, if a placebo group is not included in the study, we can never be sure if the 
new treatment is better than the placebo.  Placebo control group was the usual optional 
control group for establishing efficacy of an experimental treatment.  Now with the large 
array of proven effective treatment, ethical considerations cast doubts on the 
appropriateness of using a placebo control.  Dose response trials are possible alternatives 
but they also raise ethical problems since the low dose may not be any different than the 
placebo.  Ellenberg says that placebo controls are ethical when delaying or omitting 
available treatment has no permanent adverse consequence for the patient and as long as 
the patient are fully informed about the alternative. 
An active control may be included in the RCT, but the active control is there for 
reasons such as assay sensitivity (D’Agostino, 2005).   
   Non-inferiority placebo controlled trials are the ideal trails for evaluating medical 
treatment efficacy.  They allow for control of the placebo effect and require the smallest 
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number of patients to detect a treatment effect.  A placebo control is ethically justified if 
no standard treatment exists.  If the standard treatment has not been proven efficiency, 
then there are no risks associated with delaying treatment and escape clauses are included 
in the protocol (D’Agostino, 2005). 
 
Problems with Placebo-Control trials 
 Using a placebo control clinical trials can occur problems in non-inferiority trials.  
In some clinical studies, there are a small number of available historical placebo-
controlled studies.  For many indications, there is only one historical placebo-controlled 
trial that exist.  The estimate of a control and placebo trial from only one study is 
sometimes questioned by regulatory agencies.  These agencies feel there is not an 
adequate estimate of the variability for estimation of control versus placebo.  Variability 
is the estimate across previous clinical trials that involve the same entities.  The 
variability of control versus placebo is important for determine the margin error M for the 
non-inferiority trial.  In some studies, a placebo controlled study is not available.  In these 
situations, researchers may try to work with previous dose response studies of the active 
control.  In these studies, the marketed dose of the active control is compared with a low 
dose.  The low dose effect may or may not be an adequate substitute for a placebo effect 
(D’Agostino et al 2005).   
 An example of a no available placebo-controlled trial is the study in vancomycin-
resistant-enterococcal (VRE) infection.  In VRE studies, the cure of the infection is 
defined as a success. The product linezolid is often used as the active control comparator.  
There are no published placebo-controlled studies of linezolid.  The results of the study 
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compares high dose of linezolid versus low does of linezolid.  The results show a 
difference in success rate of 14 percent.  This approach is considered conservative and 
may underestimate the true control versus placebo.  But, this process is better then simple 
guessing the control versus placebo.  The best value to use for M the margin of error is 
also unclear (D’Agostino et al 2005)   . 
 Another problem with Placebo- control trials is Biocreep.  Biocreep is when a 
slightly inferior treatment becomes the active control for the next generation of non-
inferiority trials and so on until the active controls become no better than a placebo 
(D’Agostino et al 2005).   
  
Model Specification 
Eμ  Mean treatment effect under the experiment 
Rμ  Mean treatment effect under reference drug 
Pμ  Mean treatment effect under the placebo 
iE
X     Experimental treatment quantitative measure of efficacy 
iR
X     Reference treatment quantitative measure of efficacy 
ip
X     Placebo quantitative measure of efficacy 
En    Sample size of the Experimental 
Rn   Sample size of the reference 
pn    Sample size of the placebo 
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The non-inferiority trial for this study involves mildly asthmatic patients.  The 
primary outcome FVC (forced vital capacity) was measured after a treatment period of 
six weeks for three groups of patients.  Since the experimental treatment is under review, 
I can no give further details.  The data set consist of 74 patients.  The summary for the 
measures are given (Pigeot et. al, 2003) 
 
 
 
 
 Experimental Reference Placebo 
Mean 4.32 4.86 3.14 
Standard deviation 1.16 1.03 0.97 
Minimum 1.8 2.94 1.41 
Maximum 6.52 6.90 4.99 
Summary measures for the data set on mildly asthmatic patients 
 
 
 For the non-inferiority trials, let EX  and RX  denote quantitative measures of 
efficacy under experimental and reference treatments.  We can symbolize the problem of 
non-inferiority by 
δμμ ≤− REoH :  
Versus 
δμμ >− REoH :  
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This two sample design with an active control and an experimental group gives rises 
to a major problem.  The study does not account for assay sensitivity. To take care of 
this problem, we can use a placebo group for internal validation.  Once we include the 
placebo, we have now changed to a three-arm study (Pigeot et. al, 2003).  The three arm 
study consists of a placebo, an active reference, and the experimental treatment.  Now, 
are quantitative measures of efficacy are 
 
 
iE
X ~N( Eμ , 2σ ) , I=1,……… En  
ip
X ~N( 2,σμP ), I=1,………. pn  
iR
X ~N( 2,σμR ), I=1,………. Rn  
 
The statistical testing problem is  
δμμ ≤− REoH :  
Versus 
δμμ >− REoH :  
δ  can be chosen as a fraction f of the difference in population means Rμ  and Pμ  
such that 
)( pRf μμδ −=  
Therefore we get 
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)(: PRREo fH μμμμ −≤−  
Versus 
)(:1 PRRE fH μμμμ −>−  
For the choice of δ , there often is a difference of 20 percent that is clinically 
unimportant.  To handle this case, we choose a value 
5
1−=f  
 
Now, since  
0>− PR μμ  
And 
f+= 1θ  
0H  :  θμμ
μμ ≤−
−
PR
PE  
 
Versus 
H1:    θμμ
μμ >−
−
PR
PE  
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Prior Distribution 
The distribution for the parameter is called your prior distribution.  It represents the 
distribution of your degree of belief about the parameter prior to your observing any data.  
Bayesian methods gives a procedure for updating your prior belief about the value of the 
parameter to produce a posterior distribution for the parameter, one determined 
subsequent to having observed the outcome of an experiment bearing on the value of the 
unknown parameter. 
 
Within Bayesian analysis, prior distribution for the unknown parameters needs to be 
specified.  In many situations involving vague prior, distribution are chosen with the 
intention that they have little or no impact.  However, naïve use of vague prior 
distribution may lead to them having an influence on any inference made. 
 The purpose of a reference prior is to be uniform over the range of interest and be 
considered the possible values of the unknown parameter to be equally likely.  The 
problem is such prior distribution is that uniformity is sensitive to transformation.  
Therefore, a prior distribution that is uniform on the variance will not be uniform on the 
standard deviation. Since standard deviation = percisioniance /1var = , the prior 
distribution for the scale parameters of the random effects in the Bayesian models can be 
put on the variance, standard deviation, or precision.  I used the prior distributions 
illustration in Lambert et al (2005) paper as followed: 
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Prior 1 
2
1
σ ~Gamma(0.001,0.001) 
This is the most common used prior distribution for variance parameters.  This prior 
distribution is approximately uniform for most of the range but has a spike of probability 
mass close to zero. 
 
Prior 2 
2
1
σ ~Gamma(0.1,0.1) 
 
This is of the same distributional form  as prior 1, but with the two parameters set to 
0.1.  This provides a simple assessment of the sensitivity to the choice of these parameter 
values 
Prior 3 
Log( 2σ )~Uniform(-10,10) 
This prior distribution is uniform on the log variance scale between two specified 
parameters.   
Prior 4 
Log( 2σ )~Uniform(-10,1.386) 
This prior distribution is uniform on the log variance scale between two specified 
parameters.  This is a weakly informative prior distribution because it gives zero density 
to large values. The maximum value between-study variance can be is 4 
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Prior 5 
2σ ~Uniform(1/1000,1000) 
This prior distribution is uniform on the variance.   
 
Prior 6 
2σ ~Uniform(1/1000,4) 
This is a weakly informative version of Prior 5.  The maximum value between-study 
variance can be is 4. 
Prior 7 
2
1
σ ~Pareto(1,0.001) 
When using a Pareto Distribution with parameters α  and c a uniform prior 
distribution for kτ  on the range (0,r) can be expressed by setting α =k/2 and c= 2 /r k− .  
The values of k=2,1 and -2 give uniform prior distributions on the variance, standard 
deviation and precision scales.   
 
Prior 8 
2
1
σ ~Pareto(1,0.25) 
This is the weakly informative version of prior 7 and is equivalent to a uniform prior 
distribution for the variance in the range (0,4) 
Prior 9 
σ ~Uniform(0,100) 
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This is a uniform prior distribution on the standard deviation.  The scale for the range 
is (0,100)  
 
 
 
Prior 10 
σ ~Uniform(0,2) 
 
This is the weakly informative version of prior 9 and is a uniform distribution on the 
standard deviation with a range (0,2) 
 
Prior 11 
σ ~N(0,100) for τ >0 
This is a half normal distribution truncated at zero placed on the standard deviation 
scale. 
 
Prior 12 
σ ~N(0,1) for τ >0 
This is the weakly informative version of prior 11.  This prior gives a smaller 
variance and a low probability to values greater than 4 for the between-study variance. 
 DIC  
 For model comparison, we examine the deviance information criterion (DIC).  To 
compare between various models, we need a Bayesian model selection technique.  There 
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are many Bayesian approaches to model selection. Some examples are posterior model 
probabilities, Bayes factor, and posterior predictive checks.  However, some of these 
methods are not well defined with vague prior while the others are not automatic nor 
easily reduced to a unique, single number summary.  I used the recently developed DIC 
which is a hierarchical model generalization of AIC.  The structure of DIC allows for 
automatic computation using WINBUGS. 
 DIC consists of two components, a term that measures goodness-of-fit and a 
penalty term for increasing model complexity: 
DIC= 
___
DD p+  
The first term, 
___
D , is defined as the posterior expectation of the deviance: 
___ __ __
| |[ ( )] [ 2 ln ( | )]y yD E D E f yθ θθ θ= = −  
The better the model fits the data, the smaller is the value of 
___
D . 
 The second component,   Dp     , measures the complexity of the model by the 
effective number of parameters and is defined as the difference between the posterior 
mean of the deviance and the deviance evaluated at the posterior mean of the deviance 
and the deviance evaluated at the posterior mean  
__θ   of the parameters.  
__ __ __
| | |( ) [ ( )] ( [ ]) [ 2 ln ( | )] 2 ln ( | )D y y yp D D E D D E E f y f yθ θ θθ θ θ θ θ= − = − = − +  
 
The above expression shows that Dp  can be regarded as the expected excess of the 
true over the estimated residual information in data y conditional on θ .  Hence, Dp  can 
be interpret as the expected reduction in uncertainty due to estimation.  Rearranging 
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__ __ __
| | |( ) [ ( )] ( [ ]) [ 2 ln ( | )] 2 ln ( | )D y y yp D D E D D E E f y f yθ θ θθ θ θ θ θ= − = − = − +  
Give  
__ __
( ) DD D pθ= +  
As a result, DIC can be represented as  
__ __
( ) 2 DD D pθ= +  
 
DIC can be computed based on the MCMC sample, and is reported automatically by 
WINBUGS.  The interpretation of DIC is similar to that of the AIC., as a single-number 
summary of the relative fit between the model and the ‘true model’ generating the data, 
from the perspective of prediction, conditional on the clusters in the hierarchy.  The 
smaller the DIC the better the fit and in analogy with AIC, a difference larger than 10 is 
overwhelming evidence in favor of the better model.  The effective number of parameters 
Dp  in effect counts the random effects as a fraction, and comparing them between 
different models gives a sense of how strongly are they ‘shrunk’ by the hierarchical 
distribution assumption. 
 
Results 
 The scale parameters of the non-inferiority clinical trial in the Bayesian Model  
are tested on the prior distributions presented by Lambert et al (2005).  The data set is  
from a non-inferiority trial on mildly asthmatic patients given by Pigeot et al (2003). 
Tables 1 through 12 shows the estimated values for the parameters of the 
experimental, reference and placebo treatment.  Figure 1 through figure 12 shows the 
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posterior distributions for the parameters of the experimental, reference, and placebo 
treatment. 
   The posterior Probability is  
))((1)(
1
1 iiii PRR
M
i
E fIM
HP μμμμ −>−= ∑
=
 where i=1,……..1100 is the MCMC 
sample.  From the WINBUG model, pho symbolize the posterior probability for all 
twelve models.   
 
Discussion 
 
 In this paper, the evaluation of a non-inferiority trial involving three arms was 
performed.  I used twelve different prior distributions for the variance parameters.  One 
data set was involved in non-inferiority model.  The data was from a trial involving 
mildly asthmatic patients.    The model that involved prior 9 is considered an outlier.  The 
data obtained for the experimental standard deviation, experimental variance, placebo 
standard deviation, placebo variance, reference standard deviation, and reference variance 
is inconsistent with the other prior distribution data.  The posterior distribution for all 
twelve models is 1. The Deviance Information Criterion (DIC) gives use an indication of 
which model is the best fit.  The model with the lowest DIC is the best overall fit for the 
data.  From the DIC printout, the model involving prior 4 has the lowest DIC total 
229.351 
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Table 1: Table 1 shows the estimated values, standard deviation, Monte Carlo error 
median, and 97.5% credible interval for the experimental mean. 
 
 
emu mean sd MC error 2.5% Median 97.5
% 
Start Sample 
Prior1 4.321 0.2019 0.001991 3.919 4.321 4.72 1 11000 
Prior2 4.32 0.2012 0.001971 3.92 4.32 4.718 1 11000 
Prior3 4.32 0.2032 0.001759 3.921 4.319 4.722 1 11000 
Prior4 4.32 0.201 0.001858 3.932 4.321 4.715 1 11000 
Prior5 4.32 0.2095 0.002037 3.912 4.316 4.733 1 11000 
Prior6 4.32 0.2109 0.002042 3.898 4.319 4.74 1 11000 
Prior7 4.319 0.2112 0.001913 3.9 4.32 4.729 1 11000 
Prior8 4.321 0.2092 0.001963 3.904 4.323 4.73 1 11000 
Prior9 4.319 0.2009 0.001916 3.924 4.316 4.717 1 11000 
Prior10 4.32 0.2053 0.001906 3.912 4.32 4.729 1 11000 
Prior11 4.323 0.2052 0.002114 3.91 4.321 4.733 1 11000 
Prior12 4.32 0.2043 0.002057 3.914 4.32 4.722 1 11000 
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Table 2: Table 2 shows the estimated values, standard deviation, Monte Carlo error 
median, and 97.5% credible interval for the experimental standard deviation. 
 
 
esd Mean SD MCerror 2.5% Median 97.5% Start Sample 
Prior1 1.186 0.1488 0.001695 0.9388 1.171 1.516 1 11000 
Prior2 1.185 0.1481 0.001653 0.9388 1.17 1.514 1 11000 
Prior3 1.187 0.1492 0.001422 0.9377 1.171 1.521 1 11000 
Prior4 1.1186 0.1483 0.001442 0.9398 1.172 1.518 1 11000 
Prior5 1.224 0.1583 0.001614 0.9605 1.207 1.587 1 11000 
Prior6 1.227 0.1595 0.001755 0.9597 1.21 1.588 1 11000 
Prior7 1.225 0.1596 0.001542 0.9624 1.208 1.585 1 11000 
Prior8 1.1225 0.1579 0.00158 0.9631 1.209 1.584 1 11000 
Prior9 50.21 28.98 0.2753 2.365 50.48 97.57 1 11000 
Prior10 1.204 0.1515 0.001603 0.9496 1.19 1.541 1 11000 
Prior11 1.205 0.153 0.001542 0.9488 1.189 1.545 1 11000 
Prior12 1.2 0.1519 0.001582 0.9475 1.186 1.542 1 11000 
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Table 3: Table 3 shows the estimated values, standard deviation, Monte Carlo error 
median, and 97.5% credible interval for the experimental tau. 
 
 
 
 
etau Mean SD MC error 2.5% Median 97.5% Start  Sample 
Prior1 0.7435 0.1816 0.002099 0.4354 0.7298 1.135 1 11000 
Prior2 0.7446 0.1814 0.002069 0.4366 0.7304 1.135 1 11000 
Prior3 0.7422 0.1796 0.00156 0.4322 0.729 1.137 1 11000 
Prior4 0.7435 0.1803 0.001653 0.4347 0.7286 1.132 1 11000 
Prior5 0.7001 0.1751 0.00166 0.397 0.6861 1.084 1 11000 
Prior6 0.6973 0.1756 0.001737 0.3968 0.6828 1.086 1 11000 
Prior7 0.699 0.1751 0.001714 0.3979 0.6852 1.08 1 11000 
Prior8 0.6993 0.1747 0.001736 0.3986 0.6847 1.0781 1 11000 
Prior9 0.7422 0.1802 0.001595 0.4295 0.7291 1.141 1 11000 
Prior10 0.7215 0.1767 0.001777 0.4213 0.7066 1.109 1 11000 
Prior11 0.7218 0.1778 0.001763 0.4193 0.7077 1.111 1 11000 
Prior12 0.7267 0.1789 0.001769 0.4208 0.7107 1.114 1 11000 
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Table 4: Table 4 shows the estimated values, standard deviation, Monte Carlo error 
median, and 97.5% credible interval for the experimental variance. 
 
 
evar Mean SD MC error 2.5% Median 97.5% Start  Sample 
Prior1 1.429 0.3675 0.004133 0.8814 1.37 2.297 1 11000 
Prior2 1.427 0.3654 0.004016 0.8814 1.369 2.291 1 11000 
Prior3 1.432 0.3706 0.003727 0.8793 1.372 2.315 1 11000 
Prior4 1.429 0.3664 0.003668 0.8832 1.373 2.304 1 11000 
Prior5 1.523 0.4058 0.00425 0.9225 1.458 2.52 1 11000 
Prior6 1.531 0.4092 0.004679 0.921 1.465 2.521 1 11000 
Prior7 1.527 0.4132 0.003969 0.9262 1.459 2.514 1 11000 
Prior8 1.525 0.4038 0.004041 0.9275 1.461 2.51 1 11000 
Prior9 3361.0 2996.0 28.33 5.591 2549.0 9529.0 1 11000 
Prior10 1.473 0.3805 0.004114 0.9017 1.415 2.374 1 11000 
Prior11 1.474 0.385 0.003957 0.9002 1.413 2.386 1 11000 
Prior12 
 
1.469 0.3845 0.003767 0.8894 1.409 2.386 1 11000 
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Table 5: Table 5 shows the estimated values, standard deviation, Monte Carlo error 
median, and 97.5% credible interval for the proportion of Ho:. 
 
 
p Mean SD MC error 2.5% Median 97.5% Start  Sample 
Prior1 3.977 0.2124 0.002094 3.56 3.977 4.397 1 11000 
Prior2 3.976 0.2117 0.002091 3.561 3.976 4.396 1 11000 
Prior3 3.976 0.2153 0.001944 3.551 3.974 4.399 1 11000 
Prior4 3.975 0.2121 0.001964 3.562 3.976 4.392 1 11000 
Prior5 3.974 0.2212 0.002166 3.541 3.975 4.405 1 11000 
Prior6 3.976 0.2223 0.002085 3.533 3.975 4.412 1 11000 
Prior7 3.975 0.2233 0.002045 3.536 3.977 4.407 1 11000 
Prior8 3.977 0.2209 0.002099 3.539 3.978 4.407 1 11000 
Prior9 3.974 0.2123 0.002088 3.555 3.974 4.395 1 11000 
Prior10 3.975 0.2162 0.002027 3.544 3.976 4.392 1 11000 
Prior11 3.979 0.2179 0.002148 3.545 3.978 4.41 1 11000 
Prior12 
 
3.974 0.2156 0.002059 3.556 3.976 4.398 1 11000 
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Table 6: Table 6 shows the estimated values, standard deviation, Monte Carlo error 
median, and 97.5% credible interval for the posterior probability. 
 
 
pho Mean SD MC 
error 
2.5% Median 97.5% Start  Sample 
Prior1 1 0 9.535E-
10 
1  1 1 1 11000 
Prior2 1 0 9.535E-
10 
1 1 1 1 11000 
Prior3 1 0 9.535E-
13 
1 1 1 1 11000 
Prior4 1 0 9.535E-
13 
1 1 1 1 11000 
Prior5 1 0 9.535E-
13 
1 1 1 1 11000 
Prior6 1 0 9.535E-
13 
1 1 1 1 11000 
Prior7 1 0 9.535E-
13 
1 1 1 1 11000 
Prior8 1 0 9.535E-
13 
1 1 1 1 11000 
Prior9 1 0 9.535E-
13 
1 1 1 1 11000 
Prior10 1 0 9.535E-
13 
1 1 1 1 11000 
Prior11 1 0 9.535E-
13 
1 1 1 1 11000 
Prior12 
 
1 0 9.535E-
13 
1 1 1 1 11000 
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Table 7: Table 7 shows the estimated values, standard deviation, Monte Carlo error 
median, and 97.5% credible interval for the placebo mean 
 
 
 
 
pmu Mean SD MC error 2.5% Median 97.5% Start  Sample 
Prior1 3.135 0.2286 0.002334 2.677 3.133 3.596 1 11000 
Prior2 3.136 0.229 0.002255 2.677 3.135 3.598 1 11000 
Prior3 3.134 0.2318 0.002156 2.671 3.134 3.6 1 11000 
Prior4 3.131 0.2261 0.002152 2.675 3.131 3.5714 1 11000 
Prior5 3.136 0.2451 0.002368 2.656 3.137 3.632 1 11000 
Prior6 3.136 0.2434 0.002319 2.654 3.135 3.624 1 11000 
Prior7 3.133 0.2471 0.002125 2.654 3.131 3.632 1 11000 
Prior8 3.133 0.2431 0.002144 2.654 3.13 3.628 1 11000 
Prior9 3.135 0.229 0.002188 2.68 3.135 3.582 1 11000 
Prior10 3.136 0.234 0.002018 2.68 3.133 3.593 1 11000 
Prior11 3.137 0.2399 0.002049 2.666 3.139 3.619 1 11000 
Prior12 
 
3.132 0.2338 0.002052 2.67 3.131 3.607 1 11000 
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Table 8: Table 8 shows the estimated values, standard deviation, Monte Carlo error 
median, and 97.5% credible interval for the placebo standard deviation 
 
 
 
 
 
psd Mean SD MC error 2.5% Median 97.5% Start  Sample 
Prior1 1.012 0.1751 0.001763 0.7376 0.99 1.421 1 11000 
Prior2 1.011 0.1734 0.001786 0.7391 0.9891 1.415 1 11000 
Prior3 1.009 0.17 0.00178 0.741 0.9862 1.409 1 11000 
Prior4 1.013 0.1722 0.001884 0.7408 0.9902 1.415 1 11000 
Prior5 1.075 0.1966 0.002516 0.769 1.049 1.546 1 11000 
Prior6 1.075 0.1948 0.002425 0.7651 1.048 1.533 1 11000 
Prior7 1.077 0.2008 0.002115 0.7723 1.049 1.548 1 11000 
Prior8 1.076 0.1962 0.002195 0.7722 1.049 1.539 1 11000 
Prior9 50.2 28.9 0.278 2.698 50.17 97.36 1 11000 
Prior10 1.036 0.1787 0.00179 0.753 1.015 1.451 1 11000 
Prior11 1.042 0.1831 0.002173 0.7498 1.017 1.468 1 11000 
Prior12 
 
1.035 0.1837 0.002284 0.7518 1.009 1.454 1 11000 
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Table 9: Table 9 shows the estimated values, standard deviation, Monte Carlo error 
median, and 97.5% credible interval for the placebo tau. 
 
 
ptau Mean SD MC error 2.5% Median 97.5% Start  Sample 
Prior1 1.061  0.3477 0.003442 0.4953 1.02 1.839 1 11000 
Prior2 1.062 0.3455 0.00343 0.5 1.022 1.831 1 11000 
Prior3 1.062 0.337 0.003204 0.5037 1.028 1.822 1 11000 
Prior4 1.056 0.3412 0.003412 0.003685 1.02 1.824 1 11000 
Prior5 0.9478 0.3275 0.003873 0.4187 0.9082 1.691 1 11000 
Prior6 0.9479 0.3276 0.003485 0.4257 0.9105 1.708 1 11000 
Prior7 0.9461 0.3256 0.003301 0.418 0.9094 1.677 1 11000 
Prior8 0.9473 0.3254 0.003455 0.4224 0.9095 1.679 1 11000 
Prior9 1.057 0.3401 0.003132 0.5098 1.018 1.817 1 11000 
Prior10 1.012 0.3325 0.003123 0.4753 0.9714 1.764 1 11000 
Prior11 1.004 0.3351 0.003466 0.4641 0.9669 1.779 1 11000 
Prior12 
 
1.016 0.3353 0.003856 0.4728 0.9821 1.77 1 11000 
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Table 10: Table 10 shows the estimated values, standard deviation, Monte Carlo 
error median, and 97.5% credible interval for the placebo variance. 
 
 
pvar Mean SD MC error 2.5% Median 97.5% Start  Sample 
Prior1 1.054 0.3834 0.003899 0.544 0.9801 2.019 1 11000 
Prior2 1.052 0.3783 0.003958 0.5463 0.9783 2.001 1 11000 
Prior3 1.047 0.3708 0.004056 0.5491 0.9725 1.985 1 11000 
Prior4 1.056 0.3763 0.00417 0.5488 0.9805 2.001 1 11000 
Prior5 1.195 0.4614 0.006013 0.5914 1.101 2.39 1 11000 
Prior6 1.194 0.4522 0.005885 0.5854 1.098 2.35 1 11000 
Prior7 1.2 0.4921 0.005244 0.5964 1.1 2.396 1 11000 
Prior8 1.195 0.4581 0.005187 0.5962 1.1 2.368 1 11000 
Prior9 3356.0 2993 28.17 7.281 2517.0 9479.0 1 11000 
Prior10 1.106 0.3992 0.004107 0.567 1.03 2.105 1 11000 
Prior11 1.118 0.4126 0.005079 0.5622 1.034 2.155 1 11000 
Prior12 
 
1.106 0.4204 0.005398 0.5652 1.018 2.115 1 11000 
 
 
 
 
 
  30   
Table 11: Table 11 shows the estimated values, standard deviation, Monte Carlo 
error median, and 97.5% credible interval for the reference mean. 
 
 
 
rmu Mean SD MC error 2.5% Median 97.5% Start  Sample 
Prior1 4.853 0.2497 0.002543 4.363 4.85 5.358 1 11000 
Prior2 4.853 0.2495 0.002511 4.361 4.849 5.359 1 11000 
Prior3 4.858 0.2479 0.002588 4.364 4.855 5.353 1 11000 
Prior4 4.855 0.2503 0.002179 4.35 4.855 5.355 1 11000 
Prior5 4.862 0.2578 0.003147 4.324 4.865 5.392 1 11000 
Prior6 4.858 0.2688 0.002477 4.323 4.857 5.385 1 11000 
Prior7 4.853 0.2642 0.002466 4.326 4.851 5.376 1 11000 
Prior8 4.853 0.2632 0.00257 4.329 4.852 5.38 1 11000 
Prior9 4.862 0.2493 0.002666 4.368 4.861 5.355 1 11000 
Prior10 4.86 0.2568 0.002336 4.347 4.861 5.369 1 11000 
Prior11 4.858 0.2572 0.00253 4.355 4.854 5.366 1 11000 
Prior12 
 
4.862 0.259 0.002509 4.345 4.863 5.378 1 11000 
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Table 12: Table 12 shows the estimated values, standard deviation, Monte Carlo 
error median, and 97.5% credible interval for the reference standard deviation. 
 
 
rsd Mean SD MC error 2.5% Median 97.5% Start  Sample 
Prior1 1.072 0.1888 0.001673 0.7793 1.048 1.509 1 11000 
Prior2 1.072 0.1879 0.001584 0.7806 1.047 1.514 1 11000 
Prior3 1.078 0.1934 0.002206 0.7801 1.053 1.53 1 11000 
Prior4 1.078 0.1872 0.00172 0.783 1.054 1.515 1 11000 
Prior5 1.145 0.2151 0.003134 0.8122 1.114 1.646 1 11000 
Prior6 1.149 0.2149 0.00281 0.8111 1.12 1.661 1 11000 
Prior7 1.143 0.2149 0.002218 0.8128 1.113 1.643 1 11000 
Prior8 1.141 0.2093 0.002305 0.8128 1.112 1.632 1 11000 
Prior9 50.29 28.84 0.2448 2.556 50.29 97.73 1 11000 
Prior10 1.107 0.199 0.00209 0.8004 1.08 1.581 1 11000 
Prior11 1.107 0.1979 0.00231 0.7995 1.081 1.565 1 11000 
Prior12 
 
1.106 0.2027 0.002113 0.797 1.075 1.58 1 11000 
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Table 13: Table 13 shows the estimated values, standard deviation, Monte Carlo 
error median, and 97.5% credible interval for the reference tau. 
 
 
rtau Mean SD MC error 2.5% Median 97.5% Start  Sample 
Prior1 0.9478 0.3138 0.002776 0.4393 0.9113 1.647 1 11000 
Prior2 0.9475 0.312 0.00264 0.4366 0.9125 1.642 1 11000 
Prior3 0.9391 0.3134 0.0032 0.4273 0.9028 1.643 1 11000 
Prior4 0.9362 0.31 0.002754 0.4359 0.9004 1.632 1 11000 
Prior5 0.8394 0.2944 0.00374 0.3693 0.8054 1.516 1 11000 
Prior6 0.8344 0.2973 0.003506 0.3627 0.7978 1.52 1 11000 
Prior7 0.842 0.2961 0.003166 0.3703 0.807 1.515 1 11000 
Prior8 0.8435 0.295 0.003234 0.3755 0.8086 1.515 1 11000 
Prior9 0.9409 0.3141 0.003177 0.4285 0.9058 1.646 1 11000 
Prior10 0.8916 0.3002 0.002709 0.4001 0.857 1.561 1 11000 
Prior11 0.8911  0.3005 0.003038 0.4088 0.8556 1.565 1 11000 
Prior12 
 
0.8938 0.3022 0.002741 0.4008 0.8648 1.576 1 11000 
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Table 14: Table 14 shows the estimated values, standard deviation, Monte Carlo 
error median, and 97.5% credible interval for the reference variance. 
 
 
 
rvar Mean SD MC error 2.5% Median 97.5% Start  Sample 
Prior1 1.185 0.4406 0.00391 0.6074 1.097 2.278 1 11000 
Prior2 1.184 0.4386 0.003725 0.6093 1.096 2.292 1 11000 
Prior3 1.199 0.4646 0.005623 0.6086 1.108 2.341 1 11000 
Prior4 1.197 0.434 0.004069 0.6131 1.111 2.295 1 11000 
Prior5 1.357 0.5478 0.008286 0.6596 1.242 2.709 1 11000 
Prior6 1.367 0.5328 0.007129 0.6578 1.254 2.76 1 11000 
Prior7 1.354 0.5397 0.005413 0.6607 1.239 2.7 1 11000 
Prior8 1.346 0.5156 0.005622 0.6607 1.237 2.664 1 11000 
Prior9 3361.0 2991 25.35 6.535 2529.0 9551 1 11000 
Prior10 1.265 0.4796 0.00536 0.6406 1.167 2.5 1 11000 
Prior11 1.265 0.4751 0.005815 0.6391 1.169 2.449 1 11000 
Prior12 
 
1.265 0.5008 0.005573 0.6352 1.156 2.496 1 11000 
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Figure 1:  Figure 1 above shows posterior distributions of the experimental mean.
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Figure 2:  Figure 2 above shows posterior distributions of the experimental standard 
deviation. 
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Figure 3:  Figure 3 above shows posterior distributions of the experimental tau. 
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 Prior 1   Prior 2   Prior 3   Prior 4 
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Figure 4:  Figure 4 above shows posterior distributions of the experimental 
variance. 
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Figure 5:  Figure 5 above shows posterior distributions of the reference mean. 
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Figure 6:  Figure 6 above shows posterior distributions of the reference standard 
deviation. 
 
 
 
 
  40   
 
 
 Prior 1   Prior 2          Prior 3   Prior4 
rtau sample: 11000
    0.0    1.0    2.0
    0.0
    0.5
    1.0
    1.5
rtau sample: 11000
    0.0    1.0    2.0
    0.0
    0.5
    1.0
    1.5
rtau sample: 11000
    0.0    1.0    2.0
    0.0
    0.5
    1.0
    1.5
rtau sample: 11000
    0.0     1.0     2.0
    0.0
    0.5
    1.0
    1.5
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Figure 7:  Figure 7 above shows posterior distributions of the reference tau. 
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 Prior 1   Prior 2   Prior 3   Prior 4 
rvar sample: 11000
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Figure 8:  Figure 8 above shows posterior distributions of the reference variance. 
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Below shows the Deviance Information Criterion (DIC) for each prior distribution 
on the scale parameters for the model. 
 
ex   The experimental unit 
 
px   The placebo unit 
 
rx    The reference unit 
 
Prior 1 
 
 
 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic 
nodes 
 Dbar  Dhat  pD DIC  
ex 110.782 108.736 2.046 112.828  
px 56.651 54.575 2.076 58.728  
rx 56.110 54.053 2.057 58.166  
total 223.543 217.364 6.179 229.722  
 
 
Prior 2 
 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic 
nodes 
 Dbar  Dhat  pD DIC  
ex 110.766 108.735 2.031 112.797  
px 56.644 54.574 2.070 58.714  
rx 56.099 54.054 2.046 58.145  
total 223.509 217.363 6.146 229.656  
 
 
Prior3 
 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic 
nodes 
 Dbar  Dhat  pD DIC  
ex 110.782 108.781 2.001 112.783  
px 56.614 54.646 1.968 58.581  
rx 56.125 54.152 1.973 58.098  
total 223.520 217.579 5.942 229.462  
 
 
 
 
  43   
 
Prior 4 
 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic 
nodes 
 Dbar  Dhat  pD DIC  
ex 110.767 108.777 1.990 112.756  
px 56.595 54.661 1.934 58.529  
rx 56.110 54.154 1.956 58.066  
total 223.472 217.592 5.880 229.351  
 
 
Prior 5 
 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic 
nodes 
 Dbar Dhat pD DIC  
ex 110.957 109.106 1.851 112.808  
px 57.016 55.312 1.704 58.721  
rx 56.479 54.809 1.670 58.149  
total 224.453 219.228 5.225 229.678  
 
 
Prior 6 
 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic 
nodes 
 Dbar Dhat pD DIC  
ex 111.011 109.135 1.875 112.886  
px 56.985 55.287 1.698 58.683  
rx 56.513 54.843 1.670 58.183  
total 224.509 219.266 5.243 229.752  
 
 
Prior 7 
 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic 
nodes 
 Dbar Dhat pD DIC  
ex 110.971 108.859 2.112 113.083  
px 57.012 54.809 2.202 59.214  
rx 56.454 54.280 2.174 58.628  
total 224.437 217.948 6.489 230.926  
 
 
 
  44   
 
Prior 8 
 
 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic 
nodes 
 Dbar Dhat pD DIC  
ex 110.954 108.858 2.096 113.050  
px 56.994 54.806 2.189 59.183  
rx 56.414 54.274 2.140 58.554  
total 224.362 217.937 6.425 230.787  
 
 
 
 
 
Prior 9 
 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic 
nodes 
 Dbar  Dhat  pD DIC  
ex 110.758 108.738 2.020 112.778  
px 56.625 54.579 2.047 58.672  
rx 56.135 54.062 2.072 58.207  
total 223.518 217.379 6.139 229.657  
 
 
Prior 10 
 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic 
nodes 
 Dbar  Dhat  pD DIC  
ex 110.827 108.905 1.922 112.748  
px 56.718 54.859 1.859 58.578  
rx 56.228 54.376 1.852 58.080  
total 223.773 218.140 5.633 229.406  
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Prior 11 
 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic 
nodes 
 Dbar  Dhat  pD   DIC  
ex 110.846 108.903 1.943   112.789  
px 56.789 54.886 1.903   58.691  
rx 56.246 54.380 1.866   58.111  
total 223.521 218.169 5.712   229.591  
 
 
 
 
 
 
 
 
 
 
 
Prior 12 
 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic 
nodes 
 Dbar  Dhat  pD  DIC  
ex 110.826 108.881 1.945  112.771   
px 56.751 54.857 1.894  58.645   
rx 56.262 54.378 1.884  58.146  
total 223.839 218.116 5.723  229.562 
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APPENDIX 
Prior 1 
model{ 
for(i in 1:35){ 
ex[i]~dnorm(emu,etau); 
} 
emu~dnorm(0,0.0001); 
etau~dgamma(0.001,0.001); 
evar<-1/etau 
esd<-sqrt(evar) 
 
for(i in 1:19){ 
rx[i]~dnorm(rmu,rtau); 
} 
rmu~dnorm(0,0.0001); 
rtau~dgamma(0.001,0.001); 
rvar<-1/rtau 
rsd<-sqrt(rvar) 
 
 
for(i in 1:20){ 
px[i]~dnorm(pmu,ptau); 
} 
pmu~dnorm(0,0.0001); 
ptau~dgamma(0.001,0.001); 
pvar<-1/ptau 
psd<-sqrt(pvar) 
 
p<-emu- (1/5)*(rmu-pmu); 
pho<-step(p-0); 
} 
 
 
 
list(etau=10,rtau=10, ptau=10) 
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Prior 2 
 
model{ 
for(i in 1:35){ 
ex[i]~dnorm(emu,etau); 
} 
emu~dnorm(0,0.0001); 
etau~dgamma(0.1,0.1); 
evar<-1/etau 
esd<-sqrt(evar) 
 
for(i in 1:19){ 
rx[i]~dnorm(rmu,rtau); 
} 
rmu~dnorm(0,0.0001); 
rtau~dgamma(0.1,0.1); 
rvar<-1/rtau 
rsd<-sqrt(rvar) 
 
for(i in 1:20){ 
px[i]~dnorm(pmu,ptau); 
} 
pmu~dnorm(0,0.0001); 
ptau~dgamma(0.1,0.1); 
pvar<-1/ptau 
psd<-sqrt(pvar) 
 
p<-emu- (1/5)*(rmu-pmu); 
pho<-step(p-0); 
} 
 
 
 
 
list(etau=10,rtau=10, ptau=10) 
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Prior 3 
 
model{ 
for(i in 1:35){ 
ex[i]~dnorm(emu,etau); 
} 
emu~dnorm(0,0.0001); 
etau~dgamma(0.1,0.1); 
evar<-1/etau 
esd<-sqrt(evar) 
 
for(i in 1:19){ 
rx[i]~dnorm(rmu,rtau); 
} 
rmu~dnorm(0,0.0001); 
rtau~dgamma(0.1,0.1); 
rvar<-1/rtau 
rsd<-sqrt(rvar) 
 
for(i in 1:20){ 
px[i]~dnorm(pmu,ptau); 
} 
pmu~dnorm(0,0.0001); 
ptau~dgamma(0.1,0.1); 
pvar<-1/ptau 
psd<-sqrt(pvar) 
 
p<-emu- (1/5)*(rmu-pmu); 
pho<-step(p-0); 
} 
 
 
 
 
list(etau=10,rtau=10, ptau=10) 
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Prior 4 
  
model{ 
for(i in 1:35){ 
ex[i]~dnorm(emu,etau); 
} 
emu~dnorm(0,0.0001); 
elv~dunif(-10,1.386) 
log(evar)<-elv 
etau<-1/evar 
esd<-sqrt(evar) 
 
 
for(i in 1:19){ 
rx[i]~dnorm(rmu,rtau); 
} 
rmu~dnorm(0,0.0001); 
rlv~dunif(-10,1.386) 
log(rvar)<-rlv 
rtau<-1/rvar 
rsd<-sqrt(rvar) 
 
 
for(i in 1:20){ 
px[i]~dnorm(pmu,ptau); 
} 
pmu~dnorm(0,0.0001); 
plv~dunif(-10,1.386) 
log(pvar)<-plv 
ptau<-1/pvar 
psd<-sqrt(pvar) 
 
 
p<-emu- (1/5)*(rmu-pmu); 
pho<-step(p-0); 
} 
 
list(elv=.1,rlv=.1, plv=.1) 
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Prior 5 
model{ 
for(i in 1:35){ 
ex[i]~dnorm(emu,etau); 
} 
emu~dnorm(0,0.0001); 
evar~dunif(0,1000) 
etau<-1/evar 
esd<-sqrt(evar) 
 
for(i in 1:19){ 
rx[i]~dnorm(rmu,rtau); 
} 
rmu~dnorm(0,0.0001); 
rvar~dunif(0,1000) 
rtau<-1/rvar 
rsd<-sqrt(rvar) 
 
for(i in 1:20){ 
px[i]~dnorm(pmu,ptau); 
} 
pmu~dnorm(0,0.0001); 
pvar~dunif(0,1000) 
ptau<-1/pvar 
psd<-sqrt(pvar) 
 
p<-emu- (1/5)*(rmu-pmu); 
pho<-step(p-0); 
} 
 
 
 
 
list(evar=10,rvar=10, pvar=10) 
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Prior 6 
 
model{ 
for(i in 1:35){ 
ex[i]~dnorm(emu,etau); 
} 
emu~dnorm(0,0.0001); 
evar~dunif(0,4) 
etau<-1/evar 
esd<-sqrt(evar) 
 
for(i in 1:19){ 
rx[i]~dnorm(rmu,rtau); 
} 
rmu~dnorm(0,0.0001); 
rvar~dunif(0,4) 
rtau<-1/rvar 
rsd<-sqrt(rvar) 
 
 
for(i in 1:20){ 
px[i]~dnorm(pmu,ptau); 
} 
pmu~dnorm(0,0.0001); 
pvar~dunif(0,4) 
ptau<-1/pvar 
psd<-sqrt(pvar) 
 
 
p<-emu- (1/5)*(rmu-pmu); 
pho<-step(p-0); 
} 
 
 
 
 
list(evar=.1,rvar=.1, pvar=.1) 
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Prior 7 
model{ 
for(i in 1:35){ 
ex[i]~dnorm(emu,etau); 
} 
emu~dnorm(0,0.0001); 
etau~dpar(1,0.001); 
evar<-1/etau 
esd<-sqrt(evar) 
 
for(i in 1:19){ 
rx[i]~dnorm(rmu,rtau); 
} 
rmu~dnorm(0,0.0001); 
rtau~dpar(1,0.001); 
rvar<-1/rtau 
rsd<-sqrt(rvar) 
 
 
for(i in 1:20){ 
px[i]~dnorm(pmu,ptau); 
} 
pmu~dnorm(0,0.0001); 
ptau~dpar(1,0.001); 
pvar<-1/ptau 
psd<-sqrt(pvar) 
 
p<-emu- (1/5)*(rmu-pmu); 
pho<-step(p-0); 
} 
 
 
 
 
list(etau=.001,rtau=.001, ptau=.001) 
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Prior 8 
model{ 
for(i in 1:35){ 
ex[i]~dnorm(emu,etau); 
} 
emu~dnorm(0,0.0001); 
etau~dpar(1,0.25); 
evar<-1/etau 
esd<-sqrt(evar) 
 
 
for(i in 1:19){ 
rx[i]~dnorm(rmu,rtau); 
} 
rmu~dnorm(0,0.0001); 
rtau~dpar(1,0.25); 
rvar<-1/rtau 
rsd<-sqrt(rvar) 
 
 
for(i in 1:20){ 
px[i]~dnorm(pmu,ptau); 
} 
pmu~dnorm(0,0.0001); 
ptau~dpar(1,0.25); 
pvar<-1/ptau 
psd<-sqrt(pvar) 
 
 
p<-emu- (1/5)*(rmu-pmu); 
pho<-step(p-0); 
} 
 
 
 
 
 
list(etau=1,rtau=1,ptau=1) 
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Prior 9 
model{ 
for(i in 1:35){ 
ex[i]~dnorm(emu,etau); 
} 
emu~dnorm(0,0.0001); 
etau~dunif(0,100); 
evar<-pow(esd,2) 
esd~dunif(0,100) 
 
for(i in 1:19){ 
rx[i]~dnorm(rmu,rtau); 
} 
rmu~dnorm(0,0.0001); 
rtau~dunif(0,100); 
rvar<-pow(rsd,2) 
rsd~dunif(0,100) 
 
for(i in 1:20){ 
px[i]~dnorm(pmu,ptau); 
} 
pmu~dnorm(0,0.0001); 
ptau~dunif(0,100); 
pvar<-pow(psd,2) 
psd~dunif(0,100) 
 
 
p<-emu- (1/5)*(rmu-pmu); 
pho<-step(p-0); 
} 
 
 
 
 
 
list(etau=10,rtau=10, ptau=10) 
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Prior 10 
 
 model{ 
for(i in 1:35){ 
ex[i]~dnorm(emu,etau); 
} 
emu~dnorm(0,0.0001); 
etau<-1/evar 
evar<-pow(esd,2) 
esd~dunif(0,2) 
 
for(i in 1:19){ 
rx[i]~dnorm(rmu,rtau); 
} 
rmu~dnorm(0,0.0001); 
rtau<-1/rvar 
rvar<-pow(rsd,2) 
rsd~dunif(0,2) 
 
for(i in 1:20){ 
px[i]~dnorm(pmu,ptau); 
} 
pmu~dnorm(0,0.0001); 
ptau<-1/pvar 
pvar<-pow(psd,2) 
psd~dunif(0,2) 
 
 
 
p<-emu- (1/5)*(rmu-pmu); 
pho<-step(p-0); 
} 
 
 
 
 
 
list(esd=0.1,rsd=0.1, psd=0.1) 
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Prior 11 
model{ 
for(i in 1:35){ 
ex[i]~dnorm(emu,etau); 
} 
emu~dnorm(0,0.0001); 
etau<-1/evar 
evar<-pow(esd,2) 
esd~dnorm(0,0.01)I(0,) 
 
for(i in 1:19){ 
rx[i]~dnorm(rmu,rtau); 
} 
rmu~dnorm(0,0.0001); 
rtau<-1/rvar 
rvar<-pow(rsd,2) 
rsd~dnorm(0,0.01)I(0,) 
 
for(i in 1:20){ 
px[i]~dnorm(pmu,ptau); 
} 
pmu~dnorm(0,0.0001); 
ptau<-1/pvar 
pvar<-pow(psd,2) 
psd~dnorm(0,0.01)I(0,) 
 
 
 
p<-emu- (1/5)*(rmu-pmu); 
pho<-step(p-0); 
} 
 
 
 
 
 
 
 
 
 
 
list(esd=0.1,rsd=0.1, psd=0.1) 
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Prior 12 
model{ 
for(i in 1:35){ 
ex[i]~dnorm(emu,etau); 
} 
emu~dnorm(0,0.0001); 
etau<-1/evar 
evar<-pow(esd,2) 
esd~dnorm(0,0.1)I(0,) 
 
for(i in 1:19){ 
rx[i]~dnorm(rmu,rtau); 
} 
rmu~dnorm(0,0.0001); 
rtau<-1/rvar 
rvar<-pow(rsd,2) 
rsd~dnorm(0,0.1)I(0,) 
 
for(i in 1:20){ 
px[i]~dnorm(pmu,ptau); 
} 
pmu~dnorm(0,0.0001); 
ptau<-1/pvar 
pvar<-pow(psd,2) 
psd~dnorm(0,0.1)I(0,) 
 
 
 
p<-emu- (1/5)*(rmu-pmu); 
pho<-step(p-0); 
} 
 
 
 
 
 
list(esd=0.01,rsd=0.01, psd=0.01 
